ICAD Inc.

Last updated
[ needs update ]

iCAD Inc. is a medical-device manufacturer. Headquartered in Nashua, New Hampshire, [1] iCAD offers computer aided detection (CAD) to support detection of breast, prostate and colorectal cancers. [2] The iCAD technology platforms also include hardware and software for radiation therapy treatment. [3]

Contents

iCAD Inc.
Company type Public
Nasdaq:  ICAD
Russell Microcap Index component
Founded1984;40 years ago (1984)
Headquarters Nashua, New Hampshire, U.S.
Key people
Michael Klein (CEO) [4]
Eric Lonnqvist (CFO) [5]
Michelle Strong (COO) [5]
Website icadmed.com

History

iCAD was founded in 1984 as Howtek, Inc. [6] Howtek developed, manufactured and marketed digitizing systems or scanners. The scanners converted printed, photographic and other hard copy images to digital form for use in the graphic arts, photo finishing and medical industries. From 1984 to 2000 Howtek successfully developed a series of products that improved the quality of digital imaging while reducing the price and complexity of digitizing systems. In 2001, foreseeing a decline in the graphic arts and photo finishing industries, Howtek elected to focus solely on the medical imaging market. The company acquired Intelligent Systems Software, Inc. (ISSI) which had developed an approved computer-aided detection system for breast cancer. [7] Subsequently, the company acquired Qualia Computing, Inc. of Ohio and its subsidiary, CADx Systems, Inc. [8] These acquisitions brought together two of the three companies with FDA clearance to market CAD solutions for breast cancer in the United States.

iCad originally focused on image-analysis products designed to help radiologists and other health-care providers detect cancers early. In December 2010, iCAD expanded the company’s oncology footprint by acquiring Xoft, Inc. [9] It acquired Xoft's Axxent system, which delivers radiation therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, according to the company. The system was approved in the U.S. for early-stage breast cancer, endometrial cancer and skin cancer, as well as other varieties where radiation therapy is indicated, the initial report on the acquisition stated. [10] The shield used in the system had been cleared by the Food and Drug Administration (FDA) in June 2009 in an abbreviated process used for devices that are considered equivalent to products already on the market. That process, known as 510(k), takes less time than the procedure used to approve a new device, and it generally does not require tests on humans." [11]

iCAD continues to experience a period of growth in its cancer therapy business. Radiation treatment for breast, skin and gynecological cancers is moving from conventional external beam therapy to shorter duration, more targeted therapy. The advantages of the Xoft System, which is FDA cleared for treatment anywhere in the body, have significant potential to improve patient care and quality of life.[ citation needed ]

iCAD is also applying its patented technology and algorithms to the development of CAD solutions for use with digital mammography and CT Colonography (CTC). The company is also increasing distribution through large OEM partners, such as General Electric (GE). [12]

Tungsten particles left in test subjects

Within a week of iCAD's closing on the Xoft acquisition, the Axxent FlexiShield Mini, used with its portable radiation device, the Axxent Electronic Brachytherapy System, was found to have left test subjects "riddled ... with hundreds of tiny particles of the heavy metal tungsten in their breast tissue and chest muscles." Twenty-seven of the cases occurred at Hoag Memorial Hospital Presbyterian in Newport Beach, Orange County, California. Eleven of those women have had mammograms, and all 11 showed tungsten. Two other women were treated in a study at Karmanos-Crittenton Cancer Center in Rochester Hills, Michigan. Full implications of the mistake had not been determined as of mid-March, 2011, but the company and the FDA had executed a recall on the FlexiShield Mini and were investigating. [11]

Swedish Covenant Hospital in Chicago offered Xoft’s Axxent Electronic Brachytherapy System treatment, [13] beginning in 2008. The hospital did not participate in the study in which the Axxent FlexiShield Mini — the device that has been recalled — was used in conjunction with intraoperative breast irradiation, nor has the hospital used the Axxent FlexiShield Mini on any patients.

Starting in February, 2011, a series of parallel product liability suits have been filed in Orange Country Superior Court, totaling ten Jane Doe complainants and a number of John Doe spouses by August, 2011, per the September 30, 2011 10-Q filing by the company. [14] The first and later of the plaintiffs, who consented to the experimental treatment, were represented by lawyer Jeff Milman. [15]

In July 2011, Zach's Investment Research initiated coverage of the stock with a neutral rating and "positive on iCAD's fundamentals" but said "we believe caution is warranted until there is more clarity on the potential and likely liability related to a recently filed product liability lawsuit". [16] While the company reported "strong revenue growth" for the first nine months of 2011, it also reported lawsuit and other legal expenses of $1.5 million as a component of a "Non GAAP Adjusted EBITDA" of negative $6.8 million. [17]

In January 2013, an Inflection Point Investing stock analyst wrote in part, under "Risks": "Potential legal liability for a third-party related recall for a Xoft accessory product remains a small concern. We do not feel that this risk is material or anything to dwell upon." [18]

Reimbursement rates raised

In November, 2012, the company's products were granted a more-than-doubled reimbursement rate from U.S. Centers for Medicare & Medicaid Services "for the Company’s Xoft Axxent Electronic Brachytherapy System". [19] The news led to a spike in stock volume and the price began to move, more than doubling by mid-January 2013. [20] At that time, noting the move already made by the stock, a stock analyst reviewed the company's history and situation. With standard caveats, the analyst wrote that recent developments "could cause shares to double in a year and potentially triple over the next 24 months". [18]

Financial results

In the first quarter of 2020, iCAD had a GAAP net loss of $11.8m, and a non-GAAP adjusted net loss of $3.9m. Total revenues were $6.6m, with cash and cash equivalents of $14.3m. In April 2020, iCAD closed a registered direct offering for gross proceeds of ~$12.5 million. [21]

The company stated that they "intend to continue to invest in targeted growth initiatives such as brain cancer to drive the business over the long term." [22]

Related Research Articles

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

<span class="mw-page-title-main">Brachytherapy</span> Type of radiation therapy

Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachy is Greek for short. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, esophageal and skin cancer and can also be used to treat tumours in many other body sites. Treatment results have demonstrated that the cancer-cure rates of brachytherapy are either comparable to surgery and external beam radiotherapy (EBRT) or are improved when used in combination with these techniques. Brachytherapy can be used alone or in combination with other therapies such as surgery, EBRT and chemotherapy.

<span class="mw-page-title-main">Metoclopramide</span> Medication

Metoclopramide is a medication used for stomach and esophageal problems. It is commonly used to treat and prevent nausea and vomiting, to help with emptying of the stomach in people with delayed stomach emptying, and to help with gastroesophageal reflux disease. It is also used to treat migraine headaches.

<span class="mw-page-title-main">Medtronic</span> Irish tax-registered medical device company

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.

<span class="mw-page-title-main">Varian Medical Systems</span> American healthcare company

Varian Medical Systems is an American radiation oncology treatments and software maker based in Palo Alto, California. Their medical devices include linear accelerators (LINACs) and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies software for managing cancer clinics, radiotherapy centers, and medical oncology practices. Varian Medical Systems employs more than 7,100 people at manufacturing sites in North America, Europe, and China and approximately 70 sites globally.

Astex Pharmaceuticals ("Astex") is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.

<span class="mw-page-title-main">Regeneron Pharmaceuticals</span> American biotechnology company

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

Elekta is a global Swedish company that develops and produces radiation therapy and radiosurgery-related equipment and clinical management for the treatment of cancer and brain disorders. Elekta has a global presence in more than 120 countries, with over 40 offices around the world and about 4,700 employees.

<span class="mw-page-title-main">Tomotherapy</span> Type of radiation therapy

Tomotherapy is a type of radiation therapy treatment machine. In tomotherapy a thin radiation beam is modulated as it rotates around the patient, while they are moved through the bore of the machine. The name comes from the use of a strip-shaped beam, so that only one “slice” of the target is exposed at any one time by the radiation. The external appearance of the system and movement of the radiation source and patient can be considered analogous to a CT scanner, which uses lower doses of radiation for imaging. Like a conventional machine used for X-ray external beam radiotherapy, a linear accelerator generates the radiation beam, but the external appearance of the machine, the patient positioning, and treatment delivery is different. Conventional linacs do not work on a slice-by-slice basis but typically have a large area beam which can also be resized and modulated.

Intraoperative radiation therapy (IORT) is radiation therapy that is administered during surgery directly in the operating room.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

<span class="mw-page-title-main">Prostate brachytherapy</span> Radiation therapy technique for the treatment of cancer

Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'.

Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, which was, in turn, acquired by Boston Scientific in 2019.

<span class="mw-page-title-main">Genta (company)</span>

Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases. At that time, only Ionis Pharmaceuticals, Inc. was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA. The intent is to block expression of an aberrant protein that contributes to the disease of interest. Genta in-licensed three different antisense molecules that blocked Bcl-2, a fibroblast growth factor (FGF), and the gene c-myb, respectively.

<span class="mw-page-title-main">Hoag (health network)</span> Hospital in California, United States

Hoag is a not-for-profit regional health care delivery network in Orange County, California, that treats nearly 30,000 inpatients and 350,000 outpatients annually. Hoag consists of two acute-care hospitals, seven health centers and four urgent care centers. Hoag Hospital Newport Beach, which has served Orange County since 1952, and Hoag Hospital Irvine, which opened in 2010, are Magnet designated hospitals by the American Nurses Credentialing Center (ANCC). Hoag offers a blend of health care services that include five institutes providing specialized services in the following areas: cancer, heart and vascular, neurosciences, women’s health and orthopedics through Hoag’s affiliate Hoag Orthopedic Institute.

Isoray Inc. (Isoray) is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510(k) clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu.

<span class="mw-page-title-main">Elacestrant</span> Chemical compound

Elacestrant, sold under the brand name Orserdu, is an anticancer medication which is used in the treatment of breast cancer. It is taken by mouth.

This is a historical timeline of the development and progress of cancer treatments, which includes time of discovery, progress, and approval of the treatments.

RaySearch Laboratories is a Swedish medical technology company that develops software used in radiation therapy of cancer. The company markets its products worldwide and has subsidiaries in the United States, Singapore, Belgium, France, Germany, and the United Kingdom.

References

  1. ↑ "icad, Inc. ... At A Glance", Forbes. Retrieved 2011-03-24.
  2. ↑ Company webpage.
  3. ↑ "iCAD to Present at Two Investor Conferences in November 2016" (press release), globenewswire.com, November 10, 2016.
  4. ↑ "Leadership". www.icadmed.com. Retrieved 2020-01-09.
  5. 1 2 Susan Kelly (April 17, 2023). "iCAD, in midst of restructuring, names three new top executives". Medtech Dive.
  6. ↑ "ICAD, Inc. > Description of Business", nasdaq.com. Retrieved 2017-04-21.
  7. ↑ "Howtek to Acquire Intelligent Systems Software", medimaging.net, 5 March 2002.
  8. ↑ "iCAD Announces Merger With CADx Systems, Inc. and Qualia Computing, Inc." (press release), prnewswire.com, 1 December 2003.
  9. ↑ "iCAD to acquire electronic brachytherapy specialist Xoft" (press release), medicalphysicsweb.org, December 17, 2010.
  10. ↑ Jarzemsky, Matt, "ICad To Acquire Device Maker Xoft For $13.1M In Cash And Stock", Dow Jones Newswires, December 16, 2010 1:58 P.M. ET. Retrieved 2011-03-21.
  11. 1 2 Grady, Denise, "Riddled With Metal by Mistake in a Study", The New York Times, March 21, 2011 (March 22, 2011 p. D5 NY ed.). Retrieved 2011-03-21.
  12. ↑ "GE Healthcare and iCAD enter into Developmental Agreement"(press release), prnewswire.com, 21 November 2007.
  13. ↑ "Axxent Electronic Brachytherapy". Swedish Covenant Hospital. Retrieved 2011-03-21.
  14. ↑ "ICAD INC - FORM 10-Q ...", company U.S. Securities and Exchange Commission filing via faqs.org, November 10, 2011. Retrieved 2011-11-23.
  15. ↑ Peters, Sarah, "Hoag patient sues after experimental therapy", Daily Pilot , March 9, 2011 7:59 pm. Retrieved 2011-11-23.
  16. ↑ Marckx, Brian, CFA, "iCAD, Inc: Initiating Coverage at Neutral", Zacks.com, July 13, 2011. Retrieved 2011-11-23.
  17. ↑ "iCAD Reports Third Quarter Financial Results", press release via MarketWatch, Oct. 26, 2011, 4:49 pm EDT. Retrieved 2011-11-23.
  18. 1 2 Inflection Point Investing LLC, "Multiple Drivers Spur A Significant Inflection Point For iCAD", Seeking Alpha , January 15, 2013. Analysis by unnamed individual at IPI who was "long" (owned shares in) iCAD at time of writing. Retrieved 2013-01-17.
  19. ↑ "iCAD Reports Significantly Improved Medicare Payment for Intraoperative Radiation Therapy" (press release), via finance.yahoo.com, November 5, 2012. Retrieved 2013-01-17.
  20. ↑ iCAD page, Google Finance . Retrieved 2013-01-17.
  21. ↑ https://www.icadmed.com/assets/10Q-2020-Q1.pdf [ bare URL PDF ]
  22. ↑ "ICAD Inc (ICAD) Q1 2020 - Earnings Call Transcript". 11 May 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.